Eribulin in HER2 Negative Metastatic BrCa

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Dana-Farber Cancer Institute
Sponsor:
Information provided by (Responsible Party):
Erica Mayer, MD, MPH, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01827787
First received: April 3, 2013
Last updated: May 8, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)